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CASE ONE
▪ 21yo male with no significant medical history,
▪
▪
▪
▪

has a GTC seizure at 9AM in the presence of
two fraternity brothers
Lasting 2 minutes
He remained sleepy and confused for 30
minutes, then returned to baseline
Normal neurological and general exam, except
for an abrasion of the right side of the tongue
CBC, CMP, Tox screen, EKG are normal

THE FIRST UNPROVOKED
SEIZURE

▪ To treat or not to treat?

THE FIRST UNPROVOKED SEIZURE

▪ Approximately 10% of the population will
have at least one seizure at some point in
their life
▪ Half of these will occur during childhood
and adolescence
▪ The highest risk is before age 1
▪ The higher prevalence of unprovoked
seizures is in patients younger than 1 year
and older than 65 years

RECURRENCE RISK
FIRST study
Untreated subjects

▪ 18% at 3 months
▪ 28% at 6 months
▪ 41% at 12 months
▪ 51% at 24 months

Neurology 1993; 43; 478-483

RECURRENCE RISK
MESS study

▪ 722 treated / 721 deferred
▪ Untreated arm recurrence risk
• 6 months 26%
• 2 years 39%
• 5 years 51%
• 8 years 52%

Lancet 2005; 365: 2007-13

PREDICTORS OF A FIRST
SEIZURE RECURRENCE

▪ The risk of a recurrence is highest during
the period immediately after initial seizure
▪ There is no algorithm to predict with
absolute certainty who will or will not have
a recurrence and when that recurrence will
occur
▪ What can be summarized today is very
much the same as reported in reviews of
this same topic written over 10 years ago

RECURRENCE RISK
▪ The observational studies taken as a
whole, provide an estimate of the 2 year
recurrence risk in the range of 40%
▪ The majority of recurrence occur early with
approximately 50% within 6 months of the
initial seizure
▪ Studies with prolonged follow up periods
show that 80-90% of individuals who recur
do so within 2 years of the initial seizure

PREDICTORS OF A FIRST
SEIZURE RECURRENCE
Consistently associated with an increased risk of
recurrence in both children and adults:

1. Abnormal EEG (Epileptiform abnormality)
2. Symptomatic cause or abnormal
neurological exam

EEG
▪ The diagnostic yield of EEG in the
presence of a first seizure is substantial
▪ 50% of the patients on average have
abnormal tracings
▪ An EEG done in the first 24 hours after a
seizure has a greater probability of
detecting epileptiform abnormalities

CASE ONE
▪ Normal neurological exam
▪ Normal EEG
▪ Normal MRI brain
▪ No risk factors by history
▪ NOT TO TREAT
▪ When to treat
• Patient preference
• Two years
• Repeat studies

CASE ONE 1B
▪ Positive Babinski sign on the right
▪ Normal MRI brain
▪ No risk factors
▪ Drives a Forklift
▪ No driving for 6 months
▪ No treatment
▪ Recurred exactly at 6 months

CASE 2
▪ 15 year old female
▪ With recurrent episodes of
unresponsiveness
▪ Staring straight ahead
▪ Associated with lip smacking
▪ Lasting 2-5 minutes

CASE 2
▪ Partial seizures
▪ Abnormal MRI
▪ ? Febrile seizures as a child

MESIAL TEMPORAL SCLEROSIS

WOMENS TREATMENT RELATED
ISSUES

MANAGEMENT ISSUES FOR
WOMEN WITH EPILEPSY

▪ Management of women with epilepsy has
specific challenges
▪ Hormonal influence on seizures
▪ Interaction of AEDs w contraceptives
▪ Effect of AEDs on bone health

MANAGEMENT ISSUES FOR
WOMEN WITH EPILEPSY

▪ Potentially 1 million WWE of childbearing
age in USA
▪ 3-5 births per thousand will be to WWE
▪ Issues in women w/ epilepsy who take
AEDs during their reproductive years are
numerous and complex

MANAGEMENT ISSUES FOR
WOMEN WITH EPILEPSY
Improve:
▪ Family planning
▪ Seizure management
▪ Pregnancy outcomes
▪ Patient satisfaction

CATAMENIAL SEIZURES

CATAMENIAL SEIZURES
▪ Lacks a standard definition
▪ Reported to occur in 10-70% of women at
risk
▪ Estrogens inhibits GABA mediated
inhibition and potentiates glutamate
mediated excitation
▪ Resulting in heightened excitability
▪ Increased interictal spikes and seizures

CATAMENIAL SEIZURES
▪ Progesterone opposite effect
▪ Potentiates barbiturate like ligands at the
GABA channel
▪ Reducing interictal epileptiform discharges
▪ Fewer seizures

CATAMENIAL SEIZURES
▪ During the follicular

▪

phase (first half of
menstrual cycle)
estrogen
predominates
Second phase of the
cycle Progesterone
predominates

Image(s) have been
omitted

CATAMENIAL SEIZURES
▪ During ovulatory cycles most seizures
occur approx. 3 days before onset of
menses
▪ Persists for about 6 days
▪ These seizures appear to be triggered by
progesterone withdrawal
▪ Seizures may also occur at ovulation,
precipitated by estrogen surge

CATAMENIAL SEIZURES
▪ In anovulatory cycles seizures are more
frequent and dispersed = estrogen remains
high and progesterone low
▪ 10% of menstrual cycles in healthy women
are anaovulatory
▪ 35% are anovulatory in women with
temporal lobe epilepsy

CATAMENIAL SEIZURES
▪ Chart menses along w/ seizures for at
least 4 months
▪ A day 22 progesterone level (day 1 is the
onset of bleeding) < 5ng/mL indicates
inadequate luteal phase
▪ Distinct pattern = Catamenial seizures =
different treatment strategies = improved
control

CATAMENIAL SEIZURES
Management

▪ First line treatment: The most effective
AED monotherapy
▪ Supplemental daily dose of maintenance
AED at the time of expected seizure
exacerbation
▪ 2-3 days before the expected cluster
▪ Continue for 2 days after the usual cluster
duration

CATAMENIAL SEIZURES
Management

▪ Diamox (off label) 250-1000 mgs in two
divided doses
▪ Tolerance = Intermittent therapy
▪ 10-14 days around the time of seizure
vulnerability
▪ Should not be used in pregnant women

CATAMENIAL SEIZURES
▪ Any treatment with hormonal manipulation
should be done in collaboration w/ a GYN
▪ Oral synthetic Progestins not helpful
▪ Parenteral medroxyprogesterone (DepoProvera) given in large enough doses to
cause amenorrhea = reduction in seizure
frequency in some women

CATAMENIAL SEIZURES
▪ Natural Progesterone (extract of soy in
suppository and Lozenge form) over the
initial luteal phase of the cycle 100-200
mgs TID or QID
▪ Prometrium 100 mg capsules
▪ Progesterone topical cream
▪ Avoided in anticipation of a pregnancy and
in the absence of contraception

CATAMENIAL SEIZURES
▪ Antiestrogens: Clomiphene
▪ Reported to reduce seizures in women w/
intractable partial epilepsy
▪ Side effects:
– Hot flashes
– Polycystic ovaries
– Unplanned pregnancy
– Breast tenderness
– Ovarian overstimulation syndrome

CATAMENIAL SEIZURES
▪ Women with catamenial seizure pattern
may experience improved seizure control
after menopause
▪ During perimenopause = Irregular Cycles =
Fluctuation in gonadal steroids =
Worsened seizure frequency
▪ Postmenopausal estrogen replacement
may exacerbate seizures in some WWE

CONTRACEPTION

CONTRACEPTION
▪ Taken in combination with hepatic
cytochrome p450 enzyme inducing AED
can be ineffective
▪ 6% per year failure rate of oral
contraceptives in women taking hepatic
enzyme inducing AEDs

CONTRACEPTION
▪ Standard prescribed oral contraceptives
contain only minimal dosage of hormones
▪ Even small increases in metabolism lead
to contraceptive failure

CONTRACEPTION
▪ Levonorgestral (Norplant; progestin only
formulation) implants not a good
alternative if using enzyme inducing AEDs,
efficacy is reduced.
▪ IM medroxyprogeterone (Depo Provera)
higher dosages of progestin has not yet
been evaluated for effectiveness in WWE

CONTRACEPTION
▪ The effectiveness of hormonal
contraception in the context of enzyme
inducing AEDs remains at approximately
the same level as that of IUDs and is
superior to barrier methods of birth
control
▪ Formulations containing at least 50ug of
estradiol or mestranol are more protective

CONTRACEPTION
INTERACT
▪ Phenobarbital
▪ Phenytoin
▪ Primidone
▪ Carbamazepine
▪ Oxcarbazepine
▪ Topiramate
▪ Rufinamide
▪ Felbamate

DO NOT INTERACT
▪ Valproic Acid
▪ Gabapentin
▪ Lamotrigine
▪ Tiagabine
▪ Zonisamide
▪ Levetiracetam
▪ Lacosamide
▪ Pregabalin
▪ Vigabatrin
▪ Ezogabine

AEDs USE IN PREGNANCY

AEDs USE IN PREGNANCY
▪ 20,000 WWE become pregnant each year
▪ Seizure frequency may change during
pregnancy
▪ 35% experience increase in seizure
frequency
▪ 55% have no change
▪ 10% decrease in seizure frequency

AEDs USE IN PREGNANCY
▪ AED concentrations may change during
pregnancy
▪ Decreased gastric tone and motility
▪ Increase plasma volume
▪ Increase in renal clearance
▪ Albumin levels and protein binding decline
= Increase in free level

AEDs USE IN PREGNANCY
▪ AED most appropriate for seizure type and the
▪
▪
▪

drug producing optimal control with least side
effects remains the AED of choice for WWE
AEDs are human teratogens
A specific syndromes are no longer accepted
Fetal AED syndrome is more appropriate

AEDs USE IN PREGNANCY
▪ 90% of children born from of women with
epilepsy will be normal
▪ Fertility rate 25-33% lower than average
▪ There is no risk free anticonvulsant
▪ Major malformations occurs in 2-3 % of all
live born children
▪ 4-8% for women with epilepsy on one
seizure medication

AEDs USE IN PREGNANCY
Minor congenital malformations
▪ Facial dysmorphism
▪ Digital anomalies
▪ 6-20% infants exposed to AEDs
▪ Two-fold increase over the general
population
▪ Subtle and outgrown

AEDs USE IN PREGNANCY
Major malformations
▪ Cleft lip and palate
▪ Cardiac defects
▪ Urogenital defects
▪ 4-6% of infants born to mother w/ epilepsy
and taking older AEDs
▪ 2-4% general population

AEDs USE IN PREGNANCY
▪ Multiple AEDs at higher risk for congenital
malformations and developmental delay
▪ Higher mean AED concentrations
associated with increased malformation
risk
▪ If WWE have been free of seizures on an
AED for a period of time, discussion
regarding medication withdrawal should be
undertaken

AEDs USE IN PREGNANCY
▪ Discontinuation of AEDs may be
considered:
• Patient seizure free 2-5 years
• Single type of seizure
• Normal neurological examination and IQ
• EEG normalized with treatment

AEDs USE IN PREGNANCY
▪ Risk for seizure recurrence is cumulative
but greatest in the first 6 months after
discontinuing AEDs
▪ It is desirable, therefore, that AED
withdrawal be completed at least 6 months
before planned conception

AEDs USE IN PREGNANCY
▪ A planned pregnancy would be ideal
▪ Major risk of malformation is within the first
trimester
▪ No changes to be made after that unless
optimization of the regimen is necessary

AEDs USE IN PREGNANCY

▪ Optimize AED before pregnancy
▪ Counseling about compliance
▪ Monitoring non-protein-bound AED levels
▪ Seizures well controlled with monotherapy
= no change
▪ Changes in AEDs during pregnancy to
reduce teratogenicity is contraindicated

AEDs USE IN PREGNANCY
▪ MD usually involved after few weeks of
pregnancy
▪ At that point limited advantage to change
▪ Overlapping AEDs during change exposes
the fetus to the effect of an additional AED

AEDs USE IN PREGNANCY
▪ No consensus for frequency of AED monitoring
▪ Total AEDs levels fall throughout pregnancy
▪ Free (non protein bound) level remain constant
▪ Baseline preconception free level
▪ Repeat at the beginning of each trimester and
▪

last 4 weeks of pregnancy
AED change or dosage remains clinical based
on seizure occurrence or adverse effects

AEDs USE IN PREGNANCY

▪ Risk for poor pregnancy outcome with
optimal care is not a contraindication for
pregnancy
▪ Over 90% will have a good pregnancy
outcome
▪ A minority will have worsening of seizure
control during pregnancy

AAN Practice Parameters Update
Focus on Pregnancy (2009)

▪ Probable WWE taking AEDs no
substantial increased risk for Cesarean
delivery (moderate?)
▪ No increased risk of premature
contractions/labor/delivery
▪ But increased for WWE who smoke

AAN Practice Parameters Update
Focus on Pregnancy (2009)

▪ If seizure free 9-12 months prior pregnancy
84-92% are going to be seizure free

CASE 2
▪ 15 year old female
▪ With recurrent episodes of
▪
▪
▪
▪
▪
▪

unresponsiveness
Staring straight ahead
Associated with lip
smacking
Lasting 2-5 minutes
Partial seizures
MRI Mesial Temporal
Sclerosis
? Febrile seizures as a
child

AED CHOICE
INTERACT

▪ Phenobarbital
▪ Phenytoin
▪ Primidone
▪ Carbamazepine
▪ Oxcarbazepine
▪ Topiramate
▪ Rufinamide
▪ Felbamate

DO NOT INTERACT
▪ Valproic Acid
▪ Gabapentin
▪ Lamotrigine
▪ Tiagabine
▪ Zonisamide
▪ Levetiracetam
▪ Lacosamide
▪ Pregabalin
▪ Vigabatrin
▪ Ezogabine

FOLIC ACID SUPPLEMENTATION

▪ PHE, CBZ, and barbiturates can impair folate
▪
▪

absorption
Pre-pregnancy and early pregnancy
supplementation with folic acid for WWE during
reproductive years is recommended
Folic acid supplementation reduces primary and
secondary risk for neural tube defects in infants
of women who do not take AEDs

FOLIC ACID SUPPLEMENTATION

▪ Optimal dose is unclear, because study
supplementation has varied between 0.365 mgs/day
▪ Folic acid supplementation no less than
0.4mgs/day pre pregnancy and through
pregnancy

CASE 3
▪ 17 year old male evaluated with a first
GTC seizure
▪ Occurred in the morning shortly after
waking up
▪ Preceded by myoclonic jerks of arms
▪ Neurological and general exam are normal
▪ Blood work and MRI of the brain with
gadolinium were normal

BONE HEALTH

▪ People with epilepsy have a higher rate of
broken bones than people who do not
have seizures
▪ Fractures are 2-6 times more frequent in
patients with epilepsy compared to the
general population

BONE HEALTH
▪ Enzyme inducing AEDs: Phenytoin,
Phenobarbital, Primidone are associated
with decreased Bone Mineral Density
▪ Carbamazepine increases bone turnover
▪ Enzyme inducing agents demonstrate
• Lower vitamin D levels
• Increased bone specific alkaline
phosphatase

BONE HEALTH
Severity may be correlated with:
▪ Duration of AED exposure
▪ Number of AEDs used
▪ Type of AEDs used
▪ Inducers of cytochrome P450 most commonly
associated w/ bone disease:
–
–
–
–
–

Phenobarbital
Phenytoin
Primidone
Carbamazepine
Possibly VPA

BONE HEALTH
▪ AEDs may decrease bone mineral density
▪ Alter bone mineral metabolism
▪ Women in particular are vulnerable to the
effects of AEDs on bone health
▪ Women taking AEDs are two times more
likely to have hip fracture (study women
older 65)

BONE HEALTH
▪ In women with epilepsy osteoporosis
appears to be more prevalent
▪ Occurs at younger age

Progressive bone deficit in
epilepsy

▪ A cross-sectional evaluation
▪ 82 ambulatory children aged 6 to 18 years
▪ With epilepsy for <1 year to 6 or more
years (n = 27)
▪ Controls were 32 healthy children aged
12.8 2.6 years

Neurology, January 2008; 70:170-176

Progressive bone deficit in
epilepsy

▪ Children with epilepsy had reduced total
body mean bone mineral density
compared with control
▪ Increasing duration of epilepsy was
associated with a reduction in total bone
mineral density
▪ Boys < I year of epilepsy higher bone
density than girls

Progressive bone deficit in
epilepsy

▪ > 6 or more years of epilepsy girls had
higher bone density compared with boys
▪ Both boys and girls with epilepsy are at
risk for lower bone density
▪ The study was not powered to determine
individual antiepileptic medication effects
on bone mineral density

BONE HEALTH
▪ All patients with epilepsy should receive
adequate daily CA and vitamin D
▪ Regular exercise gravity resisting
▪ All menopausal women and patients with
prolonged AED use (>5 years), should
have a DEXA scan

BONE HEALTH
Bone disease is increased:
▪ With history of enzyme inducing AEDs
exposure
▪ Polypharmacy
▪ Longer duration of treatment

BONE HEALTH
▪ Significant declines in bone density can be
seen 1 year after initiation of AEDs
▪ The appropriate timing for the first screen
or interval for subsequent follow up is
unknown
▪ Some suggest to screen for patients on
AEDs for 2-5 years

EPILEPSY AND ALCOHOL
▪ Moderate alcohol consumption is not associated with
▪

▪
▪

▪
▪

increased seizure activity
Binge drinking and alcohol withdrawal can cause
seizures and even status epilepticus
A drink or two now and then does not increase seizure
activity
When alcohol is related to seizures, usually are
secondary alcohol withdrawal rather than drinking itself.
Alcohol withdrawal seizures 6 and 72 hours after the last
drink
Risk of seizures is increased after three or more alcoholic
beverages

EPILEPSY AND EXERCISE
▪ Aerobic
▪ Walking
▪ Jogging, running (especially on an indoor, grass, or
▪
▪
▪
▪
▪

supervised track)
Stationary bicycling (recumbent bicycle) are particularly
safe
Treadmills are generally safe (emergency stop)
Elliptical or similar devices are probably preferable to
treadmills
Exercise benefits individuals with epilepsy: including
improved seizure control, mood, and quality of life
No significant evidence to suggest that contact sports are
harmful to athletes with epilepsy

CASE 3
▪ 17 year old male evaluated
▪
▪
▪
▪

with a first GTC seizure
Occurred in the morning shortly
after waking up
Preceded by myoclonic jerks of
arms
Neurological and general exam
are normal
Blood work and MRI of the
brain with gadolinium were
normal

Image(s) have been
omitted

AED CHOICE
▪ Phenobarbital
▪ Phenytoin
▪ Primidone
▪ Carbamazepine !!!
▪ Oxcarbazepine !!!
▪ Topiramate
▪ Rufinamide
▪ Felbamate

▪ Valproic Acid
▪ Gabapentin
▪ Lamotrigine
▪ Tiagabine
▪ Zonisamide
▪ Levetiracetam
▪ Lacosamide
▪ Pregabalin
▪ Vigabatrin
▪ Ezogabine

ALWAYS DISCUSS SEIZURE
PRECAUTIONS

KEEP AN EYE ON THE GOAL
GOALS OF THE TREATMENT

–Seizure freedom
–Good quality of life
–No side effects

